guest ::
| Home > Publications database > Alzheimer's Imaging Consortium. |
| Home > Publications database > Alzheimer's Imaging Consortium. |
| Journal Article (Other) | DKFZ-2025-03047 |
; ; ; ; ; ; ; ; ;
2025
Wiley
Hoboken, NJ
Abstract: Alzheimer's disease (AD) is the most common form of dementia[1]. Despite the advances in the understanding of its main neuropathological hallmarks, a significant gap remains in comprehending this multifactorial neurodegenerative disorder. Contributing factors to AD include chronic vascular dysregulation and a prothrombotic milieu, promoting fibrin accumulation in brain vessels[2]. Fibrin, the main protein component of blood clots, is significantly increased in 60% of AD-patients' brains[3]. Furthermore, its strong interaction with amyloid-β promotes the production of degradation-resistant clots[2]. This prothrombotic milieu intensifies hypoperfusion, neurodegeneration and blood-brain barrier (BBB) disruption[4], but not in all patients. Early detection could help identify patients which might benefit from anticoagulant therapies[5]. The BioClotAD Project aims to develop an imaging biomarker based on a fibrin binding probe (FBP)[6] to non-invasively identify AD's pro-coagulant state.BioClotAD involves four partners in three European countries with complementary expertise, using extensive in vitro, ex vivoand in vivo assays, including AD animal models and human AD brain samples. Our project is based on three blocks: 1) Testing the FBP to in vivo detect the cerebral occlusions by nuclear imaging. 2) Detecting fibrin deposits inside the brain parenchyma with FBP coupled to a transferrin receptor antibody (FBP-TfR) to facilitate BBB crossing[7]. FBP-TfR will be labelled for optical and nuclear imaging. 3) Validating the most promising FBP probes in frozen brain samples of AD patients by autoradiography or fluorescence microscopy.BioClotAD provides feasible neuroimaging strategies to in vivo detect the fibrin cerebral accumulation of AD models and identify the specific regional distribution in the brain. Our project will set the basis for future clinical trials on neuroimaging of the cerebral fibrin accumulation in AD.BioClotAD neuroimaging biomarkers will allow the early detection of the pro-thrombotic state in AD, opening a window of opportunity to delay the disease progression by personalized anticoagulant therapies. References: 1. Alzheimer's Association. 2021. https://www.alz.org/media/documents/alzheimers-facts-and-figures.pdf. 2. Cortes-Canteli et al. 2020. 10.1016/j.jacc.2019.10.062 3. Cortes-Canteli, et al. 2015. https://doi.org/10.1016/j.neurobiolaging.2014.10.030 4. Cortes-Canteli, et al. 2012. https://doi.org/10.3233/JAD-2012-120820 5. Cortes-Canteli, et al. 2019. https://doi.org/10.1016/j.jacc.2019.07.081 6. Oliveira, Caravan. 2017. https://doi.org/10.1039/c7dt02634j 7. Sehlin, et al. 2019. https://doi.org/10.1007/s00259-019-04426-0.
Keyword(s): Humans (MeSH) ; Alzheimer Disease: diagnostic imaging (MeSH) ; Alzheimer Disease: metabolism (MeSH) ; Alzheimer Disease: pathology (MeSH) ; Animals (MeSH) ; Fibrin: metabolism (MeSH) ; Brain: diagnostic imaging (MeSH) ; Brain: metabolism (MeSH) ; Brain: pathology (MeSH) ; Biomarkers (MeSH) ; Disease Models, Animal (MeSH) ; Fibrin ; Biomarkers
; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; DEAL Wiley ; Essential Science Indicators ; IF >= 10 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection
|
The record appears in these collections: |
